Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma
Latest Information Update: 24 Feb 2023
Price :
$35 *
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic ductal carcinoma
- Focus Therapeutic Use
- Acronyms ACCORD; PRODIGE 24/CCTG PA.6
- 21 Jan 2023 Results (n=114) assessing RWO for pts with resected PDAC and intent for adjuvant mFFX at Memorial Sloan Kettering (MSK) presented at the 2023 Gastrointestinal Cancers Symposium
- 13 Sep 2022 Results (n=89)of Adjuvant gemcitabine is as efficient as mFOLFIRINOX in patients with GemPred+ tumor signature and resected pancreatic adenocarcinoma presented at the 47th European Society for Medical Oncology Congress
- 06 Dec 2021 Status changed from active, no longer recruiting to completed.